CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

22-334

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

20 MARCH 2009

NDA: NDA 22-334/N-000

Drug Product Name
Proprietary: Afinitor®
Non-proprietary: everolimus

Review Number: 1

Dates of Submission(s) Covered by this Review

Letter	Stamp	Review Request	Assigned to Reviewer
27 JUNE 2008	30 JUNE 2008	24 JULY 2008	29 JULY 2008
09 SEP 2008 (BC)	09 SEP 2008	n/a	n/a
20 JAN 2009 (BC)	21 JAN 2009	n/a	n/a

Submission History (for amendments only): N/A

Applicant/Sponsor
Name: Novartis Pharmaceuticals Corporation
Address: One Health Plaza
East Hanover, New Jersey 07936-1080
Representative: Sibylle R. Jennings, Ph.D.
Associate Dir. Drug Regulatory Affairs
Telephone: (862) 778-1196

Name of Reviewer: Robert J. Mello, Ph.D.

Conclusion: The application is recommended for approval from microbiology product quality standpoint.

Product Quality Microbiology Data Sheet

A. 1. **TYPE OF SUBMISSION:** New NDA

2. **SUBMISSION PROVIDES FOR:** Marketing Approval

3. **MANUFACTURING SITE:** Novartis Pharma Stein AG
Schaffhauserstrasse
CH-4332 Stein
Switzerland

4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Tablet; Oral; 5mg and 10mg

5. **METHOD(S) OF STERILIZATION:** N/A

6. **PHARMACOLOGICAL CATEGORY:** Anti-neoplastic drug

B. **SUPPORTING/RELATED DOCUMENTS:** None

C. **REMARKS:**

- The ONDQA PAL Initial Quality Assessment was submitted to DFS on 04 AUG 2008. No microbiology issues were identified in that review.
- The submission, in electronic eCTD format, was available via the Global Submit document system.
- This 505 (b)(1) application was granted Priority Review designation in DSS. There were numerous amendments to the submission (42 items within the Global submit system).
- On 30 OCT 2008 the original 30 DEC 2008 goal date was extended to the new date of March 2009 as a result of the receipt of a major amendment.
- The Afinitor® tablet (everolimus) was formerly known as "RAD001" during the development program. As a result, much of the submitted documentation refers to RAD001.

Filename: N022334N000R1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability – Recommend Approval

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable –

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The oral tablets are prepared in [redacted] b(4)

B. Brief Description of Microbiology Deficiencies - None

C. Assessment of Risk Due to Microbiology Deficiencies – N/A

III. Administrative

A. Reviewer's Signature _____
Robert Mello, Ph.D.

B. Endorsement Block_____
Bryan S. Riley, Ph.D.

C. CC Block
NDA 22-334

4 Page(s) Withheld

✓ Trade Secret / Confidential (b4)

_____ Draft Labeling (b4)

_____ Draft Labeling (b5)

_____ Deliberative Process (b5)

Withheld Track Number: Microbiology- 4

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert Mello
3/20/2009 11:23:46 AM
MICROBIOLOGIST

Recommend Approval

Bryan Riley
3/20/2009 12:28:44 PM
MICROBIOLOGIST
I concur.